Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.

ABSTRACT:

Objective

To evaluate the safety and efficacy of intravenous (IV) golimumab treatment in psoriatic arthritis (PsA).

Methods

In this phase III, randomized, double-blind, placebo-controlled trial, patients were randomly assigned to receive IV placebo (n = 239) or golimumab at 2 mg/kg (n = 241) at weeks 0, 4, 12, and 20. The primary end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at week 14. Controlled secondary end points included change from baseline in Health Assessment Questionnaire disability index (HAQ DI) score at week 14, proportions of patients with ACR50 and ACR70 responses and ≥75% improvement on the Psoriasis Area and Severity Index (a PASI75 response) at week 14, and change

SUBMITTER: Kavanaugh A 

PROVIDER: S-EPMC5765449 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature